Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activator protein 1 (AP-1) is a pleiotropic dimeric transcription factor complex primarily composed of members of the Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, Fra-2) protein families (Hess et al., 2004, J Cell Sci). It functions as a critical nuclear integrator for the Mitogen-Activated Protein Kinase (MAPK) signaling pathways, including the ERK, JNK, and p38 cascades, which regulate AP-1 activity through both post-translational phosphorylation and transcriptional induction (Shaulian and Karin, 2002, Nat Cell Biol). By binding to TPA-responsive elements (TRE) in the promoter regions of target genes, AP-1 controls fundamental cellular processes such as proliferation, differentiation, apoptosis, and the stress response.\n\nIn clinical pathology, dysregulation of AP-1 is a hallmark of various cancers, where it drives oncogenic transformation, epithelial-mesenchymal transition, and metastasis (Eferl and Wagner, 2003, Nat Rev Cancer). It also plays a central role in chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis, by driving the expression of pro-inflammatory cytokines and matrix metalloproteinases (Aikawa et al., 2008, Nat Med). Therapeutic targeting of AP-1 includes direct small-molecule inhibitors that disrupt DNA binding or dimerization, as well as indirect modulation via upstream MAPK pathway inhibitors like MEK or JNK inhibitors. However, the broad biological necessity of AP-1 across different tissues presents significant challenges for achieving therapeutic windows without systemic toxicity.
Direct inhibition of AP-1 DNA binding activity at TPA-responsive elements (TRE), disruption of the leucine zipper-mediated dimerization between Jun and Fos subunits, or indirect suppression of AP-1 activity through the inhibition of upstream Mitogen-Activated Protein Kinase (MAPK) signaling components such as MEK, ERK, and JNK (Hess et al., 2004, J Cell Sci; Aikawa et al., 2008, Nat Med).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activator protein 1 transcription factor complex (AP-1) (AP-1).